Amneal gains FDA nod for launch of Revatio® & Amicar® tablets
Category: #health  | By Mateen Dalal  | Date: 2019-12-04 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Amneal gains FDA nod for launch of Revatio® & Amicar® tablets

Amneal Pharmaceuticals, Inc. has made some consistent ripples in the generics and specialty pharmaceutical industry. Recently, the company made headlines when it revealed attaining final approval from the U.S. FDA on its ANDA (Abbreviated New Drug Applications) for generic editions of Amicar® (aminocaproic acid) Tablets USP, 500 mg and Revatio® for Oral Suspension 10 mg/ml.

According to a statement, Chintu Patel, Co-CEO, Amneal, said that their company is delighted to introduce these new drugs to healthcare providers and patients. He claims that their firm’s diverse and large pipeline has managed to deliver 36 new generic items in 2019 across multiple dosage forms.

Reportedly, Amneal had earlier bagged the designation of Competitive Generic Therapy (CGT) from the FDA for the generic version of Amicar®. Considering its first approved application, the biotech has been offered 180 days of CGT exclusivity.

Prior to this news, Amneal was in limelight for the launch of the generic version of Invega® (paliperidone). The drug was introduced in extended-release tablets ranging from 1.5mg to 9mg.

Speaking of which, Patel said that the company is pleased to get an approval for the launch of the generic version of Invega. It marks as one of 15 complex drugs that the firm expects to launch over 24-month.

Moreover, with a varied lineup of over 170 products, the company hopes to progress these types of complex product approvals, which would further expand its portfolio. Also, such moves would allow patients to buy generic medicines at affordable prices, cites Patel.

For the record, Amneal Pharmaceuticals, Inc. is based in Bridgewater, New Jersey. It is an integrated pharmaceutical firm focused on manufacturing, developing and distributing branded, generic, and biosimilar products. Amneal has operations in Asia, North America and Europe, and is working on bringing high-quality medicines to patients primarily within the U.S.
 

Source Credit: https://investors.amneal.com/news/press-releases/press-release-details/2019/Amneal-Announces-the-Approval-and-Launch-of-Generic-Revatio-for-Oral-Suspension-and-Generic-Amicar-Tablets/default.aspx

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Microsoft investigates Teams and Outlook outage that left users disrupted

Microsoft investigates Teams and Outlook outage that left users disrupted

By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

By Mateen Dalal

Britishers who rely on the budget-friendly aisles of supermarkets reportedly saw the biggest increases in food prices in the months leading up to Christmas, significantly outpacing those for luxury as well as premium brands, as per a survey. Accor...

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

By Mateen Dalal

Sun Cable, the Singapore-based solar energy company, has reportedly entered voluntary administration, despite the financial support it received from billionaire investors. The company was supposed to be working on a A$30 billion (US$21 billion) solar...